Resibufogenin Suppresses Triple-Negative Breast Cancer Angiogenesis by Blocking VEGFR2-Mediated Signaling Pathway

• Главные авторы: Ting Yang (Автор), Yi-Xin Jiang (Автор), Ye Wu (Автор), Dong Lu (Автор), Rui Huang (Автор), Long-Ling Wang (Автор), Shi-Qi Wang (Автор), Ying-Yun Guan (Автор), Hong Zhang (Автор), Xin Luan (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2021-04-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Resibufogenin (RBF), an active compound from Bufo bufonis, has been used for the treatment of multiple malignant cancers, including pancreatic cancer, colorectal cancer, and breast cancer. However, whether RBF could exert its antitumor effect by inhibiting angiogenesis remains unknown. Here, we aime...